| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Chongqing Zhifei Biological Products Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥34.21 |
| 52 Week High | CN¥70.27 |
| 52 Week Low | CN¥33.51 |
| Beta | 0.82 |
| 1 Month Change | -27.14% |
| 3 Month Change | -29.83% |
| 1 Year Change | -37.36% |
| 3 Year Change | -76.19% |
| 5 Year Change | 19.06% |
| Change since IPO | 432.45% |
Recent News & Updates
Earnings Miss: Chongqing Zhifei Biological Products Co., Ltd. Missed EPS By 35% And Analysts Are Revising Their Forecasts
Apr 26
Is Chongqing Zhifei Biological Products (SZSE:300122) A Risky Investment?
Mar 26Shareholder Returns
| 300122 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -17.2% | -0.2% | -0.3% |
| 1Y | -37.4% | -25.2% | -14.6% |
Return vs Industry: 300122 underperformed the CN Biotechs industry which returned -24.8% over the past year.
Return vs Market: 300122 underperformed the CN Market which returned -14.4% over the past year.
Price Volatility
| 300122 volatility | |
|---|---|
| 300122 Average Weekly Movement | 6.8% |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 300122's share price has been volatile over the past 3 months.
Volatility Over Time: 300122's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 6,545 | Rensheng Jiang | www.zhifeishengwu.com |
Chongqing Zhifei Biological Products Co., Ltd. engages in the research, development, manufacture, marketing, distribution, import, and export of vaccines and biological products in China. It also provides cold storage services.
Chongqing Zhifei Biological Products Co., Ltd. Fundamentals Summary
| 300122 fundamental statistics | |
|---|---|
| Market cap | CN¥81.89b |
| Earnings (TTM) | CN¥7.50b |
| Revenue (TTM) | CN¥53.14b |
10.9x
P/E Ratio1.5x
P/S RatioIs 300122 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300122 income statement (TTM) | |
|---|---|
| Revenue | CN¥53.14b |
| Cost of Revenue | CN¥39.64b |
| Gross Profit | CN¥13.50b |
| Other Expenses | CN¥6.01b |
| Earnings | CN¥7.50b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.13 |
| Gross Margin | 25.41% |
| Net Profit Margin | 14.11% |
| Debt/Equity Ratio | 15.2% |
How did 300122 perform over the long term?
See historical performance and comparison